NEXT Oncology

27/06/2025

We were thrilled to celebrate the opening of our newest location in Houston with a fun Grand Opening party.

09/06/2025

Congratulations to our colleagues at Iambic Therapeutics for continued success. Our own Andrae Vandross with NEXT - Austin had this to say: “Patients entering this study, particularly those with brain metastases, have few available treatment options. Our focus is on identifying important potential advances for these individuals and to look at novel approaches that may provide a therapeutic benefit.”

Read more here:

Designed with Iambic’s AI-Drug Discovery platform, IAM1363 is highly differentiated by its target selectivity, brain-penetrance, pan-mutant activity, and tumor enrichment

02/06/2025

We are very honored to support ongoing clinical research at American Society of Clinical Oncology (ASCO) 2025 and the Merit awards. Congratulations to Curtis Perry, recipient of the Anthony and Marilyn Tolcher Merit award and Udhayvia Grewal, recipient of the Theresa Mays Endowed Merit Award, for their outstanding work.

28/05/2025

Congratulations to our colleagues at Biohaven on continuing to advance innovative . Our own Michael Song commented: "We are excited to partner with Biohaven and dose the first patient on this important study. This is an exciting, validated target with potential to extend therapeutic benefit to several FGFR3 driven tumors."

Read more here:

20/05/2025

We are thrilled to announce that our colleague Alex Spira, MD, PhD, FACP, FASCO with NEXT Oncology Virginia has been appointed Chief Scientific Officer for NEXT Oncology worldwide.

Our founder, Anthony Tolcher, had this to say: “We are committed to offering hope when conventional treatments fall short—and that’s what being the NEXT Option is all about. Dr. Spira is a respected leader in the oncology community, and his expertise will be instrumental as we expand our Phase 1 trial capabilities and scientific leadership.”

Read more here: https://nextoncology.com/next-oncology-names-dr-alex-spira-chief-scientific-officer/

12/05/2025

At NEXT Oncology, we work with companies like Tagworks Pharma to research the NEXT Option in cancer therapies.

Tagworks initiates Phase 1 trial for TGW101, a first-in-class Click-to-Release ADC targeting TAG-72, and appoints Dr. Keith Orford as Chief Medical Officer.

01/05/2025

https://nextoncology.com/career-opportunities/

23/04/2025

April is Esophageal Cancer Awareness Month. The statistics surrounding esophageal cancer are truly alarming, which makes awareness and education so important. This April, take a few minutes to learn the facts about esophageal cancer and become familiar with the symptoms and risk factors. It could be life-saving information for you or someone you love.

21/04/2025

NEXT Oncology announces our newest location in Houston. Dr. Peter DeMaria and Dr. Jennifer Segar welcome you!

18/04/2025

Congratulations to very own Dr. David Sommerhalder for being named a San Antonio Business Journal Health Care Hero!

15/04/2025

April is Testicular Cancer Awareness Month. Testicular cancer is the most common form of cancer in 20- to 35-year-old men. Fortunately, caught early, it is highly treatable and can often be cured, according to the National Cancer Institute (NCI). Know the facts. Learn more here.

Understand the key statistics and risk factors for testicular cancer to stay informed about its prevalence and who is most at risk. Learn more here!